Jenscare Scientific Co
9877.HK
HKD8.75 -1.46%
Exchange: HKSE |
Q4 2024
Published: Dec 31, 2024

Earnings Highlights

  • EPS of $-0.09 increased by 59.6% from previous year
  • Net income of -37.62K
  • "N/A" - N/A
9877.HK
Company 9877.HK

Executive Summary

Summary of QQ4 2024 results and strategic context for Jenscare Scientific. The quarter shows a continuation of losses reflecting the company’s pre-commercial, R&D-intensive phase, with no disclosed revenue in the reported period. Despite the negative earnings, Jenscare carries a strong liquidity position and a substantial net cash footprint, providing ample runway to advance its lead product candidates, LuXValve (TTVR) and KenValve (TAVR), toward regulatory milestones and potential partnerships. The market backdrop for transcatheter valve therapies remains favorable, especially as China expands access to structural heart interventions, but execution risk remains high given clinical validation requirements and competitive dynamics.

Key Performance Indicators

Operating Income
Increasing
-46.65K
QoQ: 0.00% | YoY: 57.34%
Net Income
Increasing
-37.62K
QoQ: 0.00% | YoY: 99.96%
EPS
Increasing
-0.09
QoQ: 0.00% | YoY: 59.61%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 6.71 -0.21 +0.0% View
Q1 2025 0.00 -0.21 +0.0% View
Q4 2024 0.00 -0.09 +0.0% View
Q3 2024 0.00 -0.09 +0.0% View